XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
NATURE OF OPERATIONS (Details Narrative)
$ in Thousands
3 Months Ended
Jun. 30, 2021
USD ($)
Aug. 13, 2018
shares
IfrsStatementLineItems [Line Items]    
Issuance and sales $ 200,000  
Maximum aggregate offering price $ 50,000  
Cash fund, description The specific terms of any securities to be offered through the sales agreement with Cantor Fitzgerald, in the at the market offering, are specified in the sales agreement prospectus. The $50,000,000 of ordinary shares that may be offered, issued and sold under the sales agreement prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the Securities Act). Upon termination of the sales agreement, any portion of the $50,000,000 included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus. See Note 2, “Liquidity” and Note 14, “Capital Stock” for a further discussion.  
SalvaRx Group plc. [Member]    
IfrsStatementLineItems [Line Items]    
Percentage of voting equity interests acquired   100.00%
Number of instruments or interests issued or issuable | shares   8,050,701